DESFERAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Desferal, and what generic alternatives are available?
Desferal is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in DESFERAL is deferoxamine mesylate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desferal
A generic version of DESFERAL was approved as deferoxamine mesylate by HOSPIRA on March 17th, 2004.
Summary for DESFERAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 136 |
| Clinical Trials: | 20 |
| Patent Applications: | 3,923 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DESFERAL |
| What excipients (inactive ingredients) are in DESFERAL? | DESFERAL excipients list |
| DailyMed Link: | DESFERAL at DailyMed |
Recent Clinical Trials for DESFERAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research | Phase 2 |
| Aditya S. Pandey, MD | Phase 2 |
| Eshmoun Clinical Research Centre | Phase 3 |
Pharmacology for DESFERAL
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity |
Anatomical Therapeutic Chemical (ATC) Classes for DESFERAL
US Patents and Regulatory Information for DESFERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-002 | May 25, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DESFERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
